Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07637448 Mobocertinib Succinate EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07637448 clinical trial report covering Mobocertinib Succinate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07634848 Ivarmacitinib Behcet Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07634848 clinical trial report covering Ivarmacitinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07635290 Anlotinib Dihydrochloride Advanced biliary tract cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07635290 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126435 Culmerciclib Hormone receptor positive HER2 negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126435 clinical trial report covering Culmerciclib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07635186 AHB-137 Hepatitis B, Chronic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07635186 clinical trial report covering AHB-137, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126436 Trastuzumab Hormone receptor positive HER2 positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126436 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126420 Anlotinib Dihydrochloride Locally Advanced Clear Cell Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126420 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white spa
Latest Hotspot
8 min read
NCT07636824 S-001 Gallbladder adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07636824 clinical trial report covering S-001, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07636772 Ivonescimab Advanced Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07636772 clinical trial report covering Ivonescimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262219 HYZ2001 Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262219 clinical trial report covering HYZ2001, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07634536 Fludarabine Phosphate Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07634536 clinical trial report covering Fludarabine Phosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07635563 Acetazolamide/Dronabinol Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07635563 clinical trial report covering Acetazolamide/Dronabinol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.